.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Express Scripts
Boehringer Ingelheim
AstraZeneca
Moodys
QuintilesIMS
Harvard Business School
Chinese Patent Office
Teva

Generated: November 19, 2017

DrugPatentWatch Database Preview

Indivior Inc Company Profile

« Back to Dashboard

What is the competitive landscape for INDIVIOR INC, and what generic alternatives to INDIVIOR INC drugs are available?

INDIVIOR INC has four approved drugs.

There are four US patents protecting INDIVIOR INC drugs.

There are one hundred and thirty patent family members on INDIVIOR INC drugs in twenty-five countries.

Summary for Indivior Inc

International Patents:130
US Patents:4
Tradenames:3
Ingredients:2
NDAs:4
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
TABLET;SUBLINGUAL020733-002Oct 8, 2002DISCNYesNo► Subscribe► Subscribe► Subscribe
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
FILM;BUCCAL, SUBLINGUAL022410-002Aug 30, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
FILM;BUCCAL, SUBLINGUAL022410-001Aug 30, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Indivior Inc
SUBUTEX
buprenorphine hydrochloride
TABLET;SUBLINGUAL020732-002Oct 8, 2002DISCNYesNo► Subscribe► Subscribe► Subscribe
Indivior Inc
SUBUTEX
buprenorphine hydrochloride
TABLET;SUBLINGUAL020732-003Oct 8, 2002DISCNYesNo► Subscribe► Subscribe► Subscribe
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
FILM;BUCCAL, SUBLINGUAL022410-004Aug 10, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
FILM;BUCCAL, SUBLINGUAL022410-001Aug 30, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
FILM;BUCCAL, SUBLINGUAL022410-003Aug 10, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
FILM;BUCCAL, SUBLINGUAL022410-002Aug 30, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Indivior Inc
SUBOXONE
buprenorphine hydrochloride; naloxone hydrochloride
FILM;BUCCAL, SUBLINGUAL022410-003Aug 10, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for INDIVIOR INC drugs

Drugname Dosage Strength Tradename Submissiondate
buprenorphine hydrochloride and naloxone hydrochloride
Sulingual Film12 mg/3 mg
SUBOXONE
3/26/2014
buprenorphine hydrochloride and naloxone hydrochloride
Sublingual Film4 mg/1 mg
SUBOXONE
5/14/2013
buprenorphine hydrochloride and naloxone hydrochloride
Sublingual Film2 mg/0.5 mg and 8 mg/2 mg
SUBOXONE
10/15/2012

Non-Orange Book Patents for Indivior Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,910,031Process for forming an ingestible thin film with non-self-aggregating uniform heterogeneity► Subscribe
2,016,206,639► Subscribe
7,666,337Polyethylene oxide-based films and drug delivery systems made therefrom► Subscribe
9,108,340Process for manufacturing a resulting multi-layer pharmaceutical film► Subscribe
8,663,687Film compositions for delivery of actives► Subscribe
8,765,167Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions► Subscribe
8,900,498Process for manufacturing a resulting multi-layer pharmaceutical film► Subscribe
8,906,277Process for manufacturing a resulting pharmaceutical film► Subscribe
7,897,080Polyethylene-oxide based films and drug delivery systems made therefrom► Subscribe
7,425,292Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Indivior Inc Drugs

Country Document Number Estimated Expiration
Denmark1587504► Subscribe
Japan2011140507► Subscribe
Japan2009507854► Subscribe
Canada2473967► Subscribe
Japan5160229► Subscribe
Japan4795639► Subscribe
Singapore178265► Subscribe
Japan2011093936► Subscribe
World Intellectual Property Organization (WIPO)2008039737► Subscribe
European Patent Office1931305► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Daiichi Sankyo
Colorcon
Accenture
QuintilesIMS
Covington
Cantor Fitzgerald
Queensland Health
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot